Radiation Oncology Journal

  • 제27권3호
  • /
  • Pages.145-152
  • /
  • 2009
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

절제 불가능한 국소 진행된 췌장암에서 방사선치료의 결과분석

The Results of Radiotherapy in Locally Advanced, Unresectable Pancreatic Cancer

  • 장현수 (아주대학교 의과대학 방사선종양학교실) ;
  • 강승희 (아주대학교 의과대학 방사선종양학교실) ;
  • 김상원 (아주대학교 의과대학 방사선종양학교실) ;
  • 전미선 (아주대학교 의과대학 방사선종양학교실) ;
  • 조선미 (아주대학교 의과대학 방사선종양학교실) ;
  • 임준철 (아주대학교 의과대학 방사선종양학교실) ;
  • 오영택 (아주대학교 의과대학 방사선종양학교실) ;
  • 강석윤 (아주대학교 의과대학 종양내과학교실)
  • Jang, Hyun-Soo (Department of Radiation Oncology, Ajou University School of Medicine) ;
  • Kang, Seung-Hee (Department of Radiation Oncology, Ajou University School of Medicine) ;
  • Kim, Sang-Won (Department of Radiation Oncology, Ajou University School of Medicine) ;
  • Chun, Mi-Son (Department of Radiation Oncology, Ajou University School of Medicine) ;
  • Jo, Sun-Mi (Department of Radiation Oncology, Ajou University School of Medicine) ;
  • Lim, Jun-Chul (Department of Radiation Oncology, Ajou University School of Medicine) ;
  • Oh, Young-Taek (Department of Radiation Oncology, Ajou University School of Medicine) ;
  • Kang, Seok-Yun (Department of Medical Oncology, Ajou University School of Medicine)
  • 투고 : 2009.08.05
  • 심사 : 2009.09.04
  • 발행 : 2009.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적: 국소적으로 진행된 절제 불가능한 췌장암에서 방사선치료 및 동시화학방사선치료에 대한 치료성적과 예후 인자를 후향적으로 분석하였다. 대상 및 방법: 1994년 1월부터 2008년 8월까지 절제 불가능한 국소 진행된 췌장암으로 진단받은 환자 중 30 Gy 이상의 방사선치료를 받은 51명을 대상으로 후향적 분석을 시행하였다. AJCC 병기에 따라 IIA부터 III까지의 환자를 대상으로 하였다. 방사선치료는 중앙값 39 Gy를 조사하였고 38명에서 항암화학요법을 병행하였는데 cisplatin, 5-FU, gemcitabine을 단독 혹은 병합하여 사용하였다. 결 과: 추적관찰기간은 2~40개월(중앙값 8개월)이었다. 전체 환자의 중앙생존기간, 1년, 2년 생존율은 각각 7개월, 15.7%, 5.9%이었다. 예후에 영향을 미치는 인자로 치료 전 CA19-9, 전신수행상태, 항암화학요법의 종류가 통계적인 유의성을 보여주었다. 동시화학방사선치료군의 중앙생존기간은 8개월, 방사선단독치료군은 6개월이었다. Gemcitabine 단독 및 gemcitabine을 포함한 조합으로 치료받은 환자의 중앙생존기간은 10개월로 방사선치료만 받은 환자와 유의한 차이를 보여주었다. 재발여부를 확인할 수 있었던 23명의 환자 중 18명에서 원격전이가 발견되었고 4명의 환자에서 림프절전이가 있었다. 부분관해 혹은 안정병변을 보였던 환자 중 원발병소의 크기가 커진 환자가 14명이었다. 원격전이까지의 기간을 확인할 수 있었던 18명의 환자를 대상으로 CA19-9과의 상관관계를 분석한 결과, 치료 전 정상 CA19-9인 환자의 원격전이까지의 중앙기간이 20개월인 반면 200 U/ml 이상인 경우에는 2개월에 불과하였다. 결 론: 절제 불가능한 국소 진행된 췌장암 환자에서 gemcitabine과 방사선치료의 병합요법이 생존율 증가에 효과가 있었다. 또한 치료 전 CA19-9의 상승 정도가 환자의 예후 및 치료방향을 결정하는데 도움이 될 것으로 생각된다.

Purpose: We retrospectively studied the outcomes and prognostic factors of patients with locally advanced, unresectable pancreatic cancer who were treated with concurrent chemoradiotherapy (CCRT) or radiotherapy only. Materials and Methods: Fifty-one patients with locally advanced, unresectable pancreatic cancer (stage IIA~III) who recevied radiotherapy ($\geq$30 Gy) between January 1994 and August 2008 were reviewed retrospectively. The median radiation dose was 39 Gy. Chemotherapy consisted of gemcitabine, cisplatin, or 5-FU alone or in various combinations, and was administered concurrently with radiotherapy in 38 patients. Results: The follow-up period ranged from 2~40 months (median, 8 months). The median survival, and the 1-and 2-year overall survival (OS) rates were 7 months, 15.7%, and 5.9%, respectively. Based on univariate analysis, the baseline CA19-9, performance status, and chemotherapy regimen were significant prognostic factors. The median survival was 8 months for CCRT, and 6 months for radiotherapy alone. The patients treated with gemcitabine-containing regimens had longer survival (median, 10 months) than the patients treated with radiotherapy alone (p=0.027). Twenty-three patients were available to evaluate the patterns of failure. Distant metastases (DM) occured in 18 patients and regional recurrences were demonstrated in 4 patients. Local progression developed in 14 patients. We analyzed the association between the time-to-DM and the baseline CA19-9 levels for 18 evaluable patients. The median time-to-DM was 20 months for patients with normal baseline CA19-9 levels and 2 months for patients with baseline CA19-9 levels $\geq$200 U/ml. Conclusion: CCRT with gemcitabine-based regimens was effective in improving OS in patients with locally advanced, unresectable pancreatic cancer. We suggest that the baseline CA19-9 level is valuable in determining the treatment strategy for patients with locally advanced, unresectable pancreatic cancer.

키워드

참고문헌

  1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-1057 https://doi.org/10.1016/S0140-6736(04)15841-8
  2. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma:clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273-279 https://doi.org/10.1097/00000658-199603000-00007
  3. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995;6:19-28
  4. Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol 2005;23:4538-4544 https://doi.org/10.1200/JCO.2005.23.911
  5. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214 https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  6. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)Int J Radiat Oncol Biol Phys 1995;31:1341-1346 https://doi.org/10.1016/0360-3016(95)00060-C
  7. Ministry of Health and Welfare. Annual Report of the Korean Central Cancer Registry. 2002
  8. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-867
  9. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads＋5-fluorouracil), and high dose radiation＋5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710 https://doi.org/10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4
  10. Cohen SJ, Dobelbower R Jr, Lipsitz S, et al. A randomized phase III study of radiotherapy alone or with 5- fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005;62:1345-1350 https://doi.org/10.1016/j.ijrobp.2004.12.074
  11. Gastrointestinal Tumor Study Group. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985;56:2563-2568 https://doi.org/10.1002/1097-0142(19851201)56:11<2563::AID-CNCR2820561104>3.0.CO;2-0
  12. McCracken JD, Ray P, Heilbrun LK, et al. 5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas:a Southwest Oncology Group Study. Cancer 1980;46:1518- 1522 https://doi.org/10.1002/1097-0142(19801001)46:7<1518::AID-CNCR2820460703>3.0.CO;2-S
  13. Kornek GV, Potter R, Selzer E, et al. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys 2001;49: 665-671 https://doi.org/10.1016/S0360-3016(00)01388-2
  14. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293-1302 https://doi.org/10.1016/S0360-3016(01)02740-7
  15. Brunner TB, Grabenbauer GG, Klein P, et al. Phase Itrial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:144-153 https://doi.org/10.1016/S0360-3016(02)03818-X
  16. Wilkowski R, Thoma M, Heinemann V, et al. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer:feasible and effective. Strahlenther Onkol 2003;179:78-86 https://doi.org/10.1007/s00066-003-1036-x
  17. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer:gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;57:98-104
  18. Talamonti MS, Catalano PJ, Vaughn DJ, et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000;18:3384-3389 https://doi.org/10.1200/JCO.2000.18.19.3384
  19. Haddock MG, Swaminathan R, Foster NR, et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007;25:2567-2572 https://doi.org/10.1200/JCO.2006.10.2111
  20. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy,infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592-1599 https://doi.org/10.1093/annonc/mdn281
  21. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil: an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-378
  22. 2007Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-331 https://doi.org/10.1200/JCO.2006.07.5663
  23. Park JH, Kim WC, Kim HJ, Gwak HK. Comparing concurrent chemoradiotherapy to chemotherapy alone for locally advanced unresectable pancreatic cancer. J Korean Soc Ther Radiol Oncol 2009;27:64-70 https://doi.org/10.3857/jkstro.2009.27.2.64
  24. Furukawa H, Okada S, Saisho H, et al. Clinicopathologic features of small pancreatic adenocarcinoma: a collective study. Cancer 1996;78:986-990 https://doi.org/10.1002/(SICI)1097-0142(19960901)78:5<986::AID-CNCR7>3.0.CO;2-A
  25. Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 1996;12:267-271 https://doi.org/10.1097/00006676-199604000-00009
  26. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 2001;24:547-550 https://doi.org/10.1097/00000421-200112000-00003
  27. Brasiunas V, Brasiuniene B, Juozaityte E, Barauskas G. Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer. Medicina (Kaunas)2004;40:1074-1080
  28. Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41 https://doi.org/10.1385/IJGC:32:1:35
  29. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005;93:740-743 https://doi.org/10.1038/sj.bjc.6602760
  30. Ziske C, Schlie C, Gorschluter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-1417 https://doi.org/10.1038/sj.bjc.6601263
  31. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801-808 https://doi.org/10.1016/j.ijrobp.2006.12.053